Bionano Genomics, Inc.
BNGO
$1.14
-$0.02-1.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.60% | 21.31% | -13.36% | -26.37% | -23.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.60% | 21.31% | -13.36% | -26.37% | -23.86% |
| Cost of Revenue | -4.09% | -72.47% | -37.22% | -40.81% | -42.70% |
| Gross Profit | -0.53% | 139.90% | 34.51% | 4.04% | 40.16% |
| SG&A Expenses | -25.88% | -4.23% | -27.78% | -54.21% | -37.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.42% | -44.58% | -38.35% | -57.91% | -48.70% |
| Operating Income | 27.68% | 62.27% | 50.64% | 68.28% | 58.15% |
| Income Before Tax | 60.75% | 80.80% | 57.73% | 90.16% | 54.19% |
| Income Tax Expenses | 3,400.00% | -41.67% | -61.54% | 138.89% | 102.78% |
| Earnings from Continuing Operations | 60.58% | 80.78% | 57.74% | 90.13% | 54.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.58% | 80.78% | 57.74% | 90.13% | 54.15% |
| EBIT | 27.68% | 62.27% | 50.64% | 68.28% | 58.15% |
| EBITDA | 33.54% | 63.94% | 57.94% | 74.69% | 61.40% |
| EPS Basic | 93.70% | 94.85% | 86.17% | 96.78% | 81.51% |
| Normalized Basic EPS | 90.01% | 90.08% | 88.18% | 96.26% | 89.19% |
| EPS Diluted | 93.70% | 94.85% | 86.17% | 96.78% | 81.51% |
| Normalized Diluted EPS | 90.01% | 90.08% | 88.18% | 96.26% | 89.19% |
| Average Basic Shares Outstanding | 525.33% | 273.03% | 205.60% | 206.48% | 148.00% |
| Average Diluted Shares Outstanding | 525.33% | 273.03% | 205.60% | 206.48% | 148.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |